Akzo Nobel announces further approval for OBS sale
Amsterdam, the Netherlands, November 16, 2007 - Schering-Plough
Corporation has received antitrust clearance from the U.S. Federal
Trade Commission (FTC) regarding its planned acquisition of Organon
BioSciences N.V. (OBS) from Akzo Nobel N.V.
In connection with the conditional FTC clearance, Schering-Plough and
the OBS animal health business, Intervet, will divest three poultry
vaccines in the United States. No divestitures of human health
products are required.
The EUR 11 billion deal was announced in March and Schering-Plough
has already received approval for the transaction from the European
Akzo Nobel and Schering-Plough continue to expect the deal to be
completed by the end of 2007.
- - -
Note to editors
Akzo Nobel is a Fortune Global 500 company and is listed on Euronext
Amsterdam. It is also the Chemicals Industry leader on the Dow Jones
Sustainability Indexes and Akzo Nobel is included on the FTSE4Good
Index. Based in the Netherlands, we are a multicultural organization
serving customers throughout the world with coatings, chemicals and
human and animal healthcare products. We employ around 62,000 people
and conduct our activities in these four segments, with operating
subsidiaries in more than 80 countries. Consolidated revenues for
2006 totaled EUR 13.7 billion. The financial results for the year
2007 will be published on March 6, 2008.
Not for publication - for more information
Akzo Nobel N.V.
Corporate Media Relations, tel. +31 20 502 7833
Contact: Marc Michelsen